Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 2, 2001, Pages 345-352

  Panhans Groß, Andrea ^a   Novak, Natalija ^a   Kraft, Stefan ^a   Bieber, Thomas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Atopic dermatitis; Costimulatory molecules; Dendritic cells; FK506; FKBP; Skin immune system; methasone valerate

Indexed keywords

B7 ANTIGEN; BETAMETHASONE VALERATE; CD40 ANTIGEN; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LANGERHANS CELL; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN ALLERGY;

EID: 0035116403     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.112600     Document Type: Article

References (46)

1. Effect of FK-506 on human mixed lymphocyte reaction in vitro
2. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro
3. Effects of chloroquine on antigen-presenting functions of epidermal cells from normal and psoriatic skin
4. Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro
5. Direct effects of glucocorticosteroids on epidermal Langerhans cells
6. The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro
7. Peptidylproline cis-trans-isomerases: Immunophilins
8. Studies on FK506 in experimental organ transplantation
9. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs
10. FK 506 for liver, kidney, and pancreas transplantation
11. Immunosuppression of canine, monkey, and baboon allografts by FK 506: With special reference to synergism with other drugs and to tolerance induction
12. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp)
13. The mechanism of action of cyclosporin A and FK506
14. The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promoter
15. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid
16. Systemic tacrolimus (FK 506) is effective for the treatment of Psoriasis in a double-blind, placebo-controlled study
17. Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis
18. Topical FK506: Suppression of allergic and irritant contact dermatitis in the guinea pig
19. Topical FK506 - Clinical potential or laboratory curiosity?
20. Inhibition of contact allergy reactions by topical FK506
21. Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin diseases?
22. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses
23. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment
24. Tacrolimus ointment for atopic dermatitis
25. A short-term trial of tacrolimus ointment for atopic dermatitis
26. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
27. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (FceRI)
28. Epidermal Langerhans cells from normal human skin bind monomeric IgE via FcεRI
29. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema
30. Langerhans cell phenotyping: A new tool for differential diagnosis of inflammatory skin diseases
31. FcεRI-expressing antigen-presenting cells: New players in the atopic game
32. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro
33. FK506 in the treatment of inflammatory skin disease: Promises and perspectives
34. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs
35. Anti-inflammatory effect of FK-506 on human skin mast cells
36. Characterization of the anti-inflammatory effect of FK-506 on human mast cells
37. The skin immune system: Progress in cutaneous biology
38. Induction of FcεR2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon
39. FK 506: Historical perspectives
40. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
41. Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats
42. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle
43. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus
44. Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: Differential regulation by T helper type I and T helper type 2 cytokines
45. Requirement of CD28-CD86 co-stimulation in the interaction between antigen-primed T helper type 2 and B cells
46. An assay for the detection of interleukin-1 synthesis inhibitors: Effects of antirheumatic drugs